Sirnaomics Considers Hong Kong for Ocular Disease Rx Trial, Advances Wound-Healing Program

A company official said Hong Kong may be the best place to conduct the phase I study since data collected may be used in both US and Chinese regulatory filings.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.